Capital Impact Advisors, LLC Veracyte, Inc. Transaction History

Capital Impact Advisors, LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$21.0 - $29.1 $36,141 - $50,081	-1,721 Reduced 7.33%	21,767 $482,000
Q4 2023 Feb 14, 2024	SELL	$19.72 - $28.68 $186,965 - $271,915	-9,481 Reduced 28.76%	23,488 $646,000
Q3 2023 Nov 14, 2023	BUY	$22.33 - $29.92 $254,986 - $341,656	11,419 Added 52.99%	32,969 $736,000
Q2 2023 Aug 14, 2023	BUY	$20.96 - $26.99 $186,397 - $240,022	8,893 Added 70.26%	21,550 $548,000
Q1 2023 May 23, 2023	BUY	$20.58 - $27.89 $181,783 - $246,352	8,833 Added 230.99%	12,657 $282,000
Q3 2022 Nov 21, 2022	BUY	$16.58 - $27.9 $63,401 - $106,689	3,824 New	3,824 $103,000
Q2 2021 Aug 17, 2021	SELL	$32.94 - $56.62 $1.09 Million - $1.88 Million	-33,134 Closed	0 $0
Q1 2021 May 18, 2021	SELL	$44.47 - $81.38 $6.53 Million - $12 Million	-146,866 Reduced 81.59%	33,134 $1.78 Million
Q4 2020 Feb 12, 2021	BUY	$32.49 - $61.88 $5.85 Million - $11.1 Million	180,000 New	180,000 $8.81 Million

254

82.1M

42.3K

18.2K

Ticker VCYT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 71,575,904
Market Cap $2.36B
Description
Veracyte, Inc. operates as a diagnostics company worldwide. The company offers Afirma Genomic Sequencing Classifier and Xpression Atlas, which are used to determine patients with indeterminate results are benign to avoid unnecessary surgery; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer ...

Get notified when there are updates to the investment portfolio of Capital Impact Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Capital Impact Advisors, LLC with notifications on news.